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Purpose
MicroRNAs (miRNAs) regulate various cellular functions, including development, cell prolif-
eration, apoptosis, and tumorigenesis. Different signatures associated with various tissue
types, diagnosis, progression, prognosis, staging, and treatment response have been iden-
tified by miRNA expression profiling of human tumors. miRNAs function as oncogenes or
as tumor suppressors. The relationship between gastric cancer and miRNA garnered atten-
tion due to the high incidence of gastric cancer in Asian countries. miR-222/221 expression
increases in gastric tumor tissues. The oncogenic effect of miR-222/221 was previously
determined in functional studies and xenograft models. In this study, transgenic mice over-
expressing miR-222/221 were generated to confirm the effect of miR-222/221 on gastric
carcinogenesis. 
Materials and Methods
At 6 weeks of age, 65 transgenic mice and 53 wild-type mice were given drinking water
containing N-nitroso-N-methylurea (MNU) for 5 alternating weeks to induce gastric cancer.
The mice were euthanized at 36 weeks of age and histologic analysis was performed. 
Results
Hyperplasia was observed in 3.77% of the wild-type mice and in 18.46% of the transgenic
mice (p=0.020). Adenoma was observed in 20.75% of the wild-type mice and 26.15% of
the transgenic mice (p=0.522). Carcinoma was observed in 32.08% of the wild-type mice
and 41.54% of the transgenic mice (p=0.341). The frequency of hyperplasia, adenoma,
and carcinoma was higher in transgenic mice, but the difference was statistically significant
only in hyperplasia.   
Conclusion
These results suggest that hyperplasia, a gastric pre-cancerous lesion, is associated with
miR-222/221 expression but miR-222/221 expression does not affect tumorigenesis itself. 
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs of
about 22 nucleotides in length; they function as post-tran-
scriptional regulators by base-pairing with the complemen-
tary sites at the 3-untranslated region of mRNA. Since
miRNA was identified, many studies of small regulators
have been published [1]. miRNAs can control the stability of
target mRNA and the efficiency of translation [2]. The latest
version of the miRBase database (Release 18) includes 1,921
miRNAs from humans [3]. Bioinformatic analyses predict
that miRNAs may regulate almost all of the human protein-
coding genes [4]. Each miRNA is predicted to suppress over
hundreds of target genes by target prediction programs. In
other words, each target mRNA can be repressed by different
miRNAs. Since the importance of miRNAs was magnified,
many efforts have been made to identify miRNA target genes
for individual miRNA using computational and experimen-
tal approaches. 
Until now, various functions of miRNAs have been sug-
gested, ranging from development to the life span of many
diseases, especially for cancer [5]. Many targets of miRNAs
are also related to human diseases, especially to cancer. For
instance, cell cycle regulators, tumor suppressor genes, onco-
genes, growth factors, and various genes regulating cell
growth are targets of miRNAs that relate to cancer. These
findings suggest that aberrant alterations of miRNA levels
are linked to human malignancy [6]. Recent studies showed
that, by regulating the expression of oncogenes and tumor
suppressor genes, miRNAs may play critical roles in main-
taining cellular homeostasis. Based on the broad scope of the
target genes regulated by miRNAs, it is important to deter-
mine the role of various miRNAs and incorporate these func-
tions into cellular signaling pathways in order to apply these
findings to treatment of diseases.
Gastric cancer is the second most common cause of death
from cancer worldwide, especially in many Asian countries,
including China, Japan, and Korea. It is responsible for about
10% of tumor-related deaths worldwide [7]. Gastric cancer
received international attention because of its high incidence
and mortality rates in Eastern Asia [8]. Although the level of
cell cycle regulators is known to be abnormal in gastric can-
cer, the molecular pathology of gastric cancer is not yet com-
pletely understood [9]. Because of the importance of gastric
cancer in Eastern Asia, many groups studied the relation 
between microRNAs and human gastric malignancy. Differ-
ential expression of microRNAs in gastric cancer has been
recently shown [10]. Furthermore, functional studies of 
microRNAs in gastric cancer have been reported by many
groups [11,12]. In a previous study, our group investigated
human miRNA profiles in gastric carcinoma compared to
matched normal gastric tissue using miRNA microarray [13].
The miR-222/221 cluster, one of the most upregulated clus-
ters, was selected as a candidate oncogene miRNA in gastric
carcinoma. From this finding, we speculated that miR-222/
221 overexpression in transgenic mice would promote gastric
carcinogenesis by suppressing the target genes of miR-222/
221, p27, and the CDK inhibitor, thereby helping cancer cells
to overcome the cell-cycle checkpoint [13]. 
In the present study, a miR-222/221 transgenic mouse
model was generated to provide further evidence supporting
the carcinogenic effect of miR-222/221. N-methyl-N-nitro-
sourea (MNU), an alkylating agent that induces adenomas
and adenocarcinomas in the stomach, was administered to
the mice to induce gastric carcinogenesis [14,15]. The goals
of the present study were to clarify the role of miR-222/221
in gastric carcinogenesis not only in vitro, but also in vivo by
assessing the phenotype of the generated transgenic mice
and by validating the suppressive effect of miR-222/221 on
target genes such as p27 and p57.
Materials and Methods
1. Animals 
All mice were housed in an air-conditioned room under
adequate temperature (20.7°C-22.8°C) and humidity (41.6%-
59.9%) control with a 12-hour dark/light cycle and free 
access to water and food (Lab diet 5002, LabDiet, Richmond,
IN). All animal experiments were performed after receiving
approval from the Institutional Animal Care and Use Com-
mittee (IACUC) of Clinical Research Institute at Seoul 
National University Hospital (SNU-070509-4), and the 
National Research Council (NRC) guidelines for the care and
use of laboratory animals were followed (revised in 1996). 
To produce miR-222/221 transgenic mice, miR-222/221
was first amplified using C57/BL6J mice. It was cloned into
pGEM-T easy vector and subsequently transferred into the
pcDNA3 vector using the BamHI and XhoI sites. The 
nucleotide sequence of the plasmid was confirmed by 
sequencing. The plasmid was then injected into fertilized
eggs. Quantitative polymerase chain reaction screening was
performed to verify that the transgene was transferred to the
mice. Genomic DNA was extracted from the tail of each
mouse. The presence of the miRNA-222/221 transgene was
assessed by using LaboPass Tissue Mini DNA Purification
Kit (Cosmo Genetech, Seoul, Korea) according to the manu-
facturer's protocol. The primer sequences are listed in Sup-
plementary Table 1. 
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2. MNU treatment
MNU (Sigma Chemical Co., St. Louis, MO) was dissolved
in distilled water at a concentration of 240 ppm and added
to drinking water in light-shielded bottles. It was freshly pre-
pared thrice per week. At 6 weeks of age, mice from each
group were given drinking water containing MNU on alter-
nating weeks for a total of 10 weeks of exposure as previ-
ously described [16]. At the end of the treatment, the drin-
king water was replaced by autoclaved distilled water. 
3. Experimental design
A total of 53 wild-type mice and 65 transgenic mice were
used. At 6 weeks of age, mice from each group were treated
with MNU five times during alternate weeks. The animals
were carefully autopsied at 36 weeks of age, under anesthe-
sia. At the end of the experiment, all mice were fasted for 24
hours, but had free access to water. Prior to euthanasia, blood
samples were collected from the vena cava for blood chem-
istry tests. The stomachs and other organs were carefully 
examined macroscopically. After pathologic observation of
the stomach and intestine, immunohistochemistry and vali-
dation studies were performed (Fig. 1).
4. Tissue preparation and immunohistochemistry
All mice underwent a thorough postmortem examination
at the time of euthanasia. The stomach was tied with silk
thread at the esophagus and duodenum and then removed.
Thereafter, phosphate buffered saline was injected into the
stomach and 10 minutes later, the stomach was excised along
the greater curvature with scissors and fixed with a pin. Half
of the excised stomach was frozen in liquid nitrogen for 
molecular biology experiments and the remaining stomach
was fixed for 24 hours, processed by standard methods, 
embedded in paraffin, sectioned at 5 µm, and stained with
hematoxylin and eosin (H&E). The intestine was removed
from the abdomen and tied with silk thread at the duodenum
and the edge of the rectum. It was then injected with 10%
neutral buffered formaldehyde solution. Twenty-four hours
later, the knots were untied, the intestine was excised longi-
tudinally with scissors and the contents were carefully 
removed. Next, the segment was rolled up longitudinally,
with the mucosa outwards, using forceps [13]. Finally, the
intestine was placed in a fixative for paraffin-wax embedding
and sectioned. The 5-µm-thick sections were stained with
H&E. Formalin-fixed, paraffin-embedded, 4-µm sections were
dewaxed in xylene, rehydrated through graded alcohol, and
placed in an endogenous peroxide block for 15 minutes. Sec-
Wild type mouse 
(n=53)
Mice aged 6 weeks treated with MNU
  5 times during alternate week
miR-222/221 transgenic mouse 
(n=65)Group
Mice were sacrificed on week 36
Immunohistochemistry and
  pathologic observation
60 8 10 12 14 36
MNU treatment
(240 ppm) Sacrifice
Fig. 1. Schematic diagram of the study design indicating that mice were observed for 36 weeks, followed by immunohisto-
chemical analysis. MNU, N-nitroso–N–methylurea.
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tions were washed in water, antigen retrieved, and then
placed in citrate buffer. Nonreactive staining was blocked by
treating sections with 1% horse serum in Tris-buffered saline
(pH 6.0) for 3 minutes.
Anti-CD31 (1:80, goat polyclonal, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti–Ki-67 (1:200, rat monoclonal,
DAKO, Glostrup, Denmark), anti-cleaved caspase-3 (1:100,
rabbit monoclonal, Cell Signaling, Danvers, MA), anti-p27
(1:500, rabbit polyclonal, Santa Cruz Biotechnology), and
anti-p57 (1:300, rabbit monoclonal, Epitomics, Burlingame,
CA) were then applied. Antibody binding was detected
using an avidin-biotin-peroxidase complex (Universal Elite
ABC Kit, Vectastain, Burlingame, CA) for 10 minutes. 
Diaminobenzidine tetrahydrochloride solution (Kit HK153-












































































































































Fig. 2. Phenotype of miR-222/221 transgenic (TG) mice and selection. (A) miR-222/221 expression was confirmed in the
stable cell line by northern blot analysis. Pre-miRNA-222/221 and mature miRNA-222/221 levels were increased in the
stable cell line transfected with miR-222/221. (B) miR-222/221 expression was assessed by polymerase chain reaction analysis
with the CMV promoter and miR-222 primers in offsprings to select TG or wild-type (WT) mice. Mouse 1, 2, and 4 were
generated from a TG mouse. (C) miR-222/221 expression level in various organs from miR-222/221 TG and WT mice. 
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5. Northern blot analysis
Total RNA was extracted from mouse tissues by using TRI-
zol reagent (Invitrogen, Carlsbad, CA) and 30 µg was loaded
on a 12.50% urea-polyacrylamide gel. The resolved RNA was
transferred to a Zeta-Probe GT blotting membrane (Bio-Rad
Laboratories, Hercules, CA) by capillary method and fixed
by ultraviolet crosslinking. Oligonucleotides complementary
to each miRNA were end-labeled at the 5-end with 32P--
ATP using T4 polynucleotide kinase (Takara, Tokyo, Japan)
and used as probes. Prehybridization and hybridization were
carried out using ExpressHyb Hybridization Solution (Taka-
ra) according to the manufacturer's instructions. The seque-
nces of the antisense oligos are complimentary to mature
miR-222 and miR-221. The sequences of the probes are
shown in Supplementary Table 1. Membranes were prehy-
bridized for 30 minutes at 37°C using hybridization solution
in hybridization tubes. Subsequently, the probes were added
into the tubes and incubated for 1 hour at 37°C. After 
hybridization, the membranes were washed twice for 30
minutes using buffer 1 (0.05% sodium dodecyl sulphate
[SDS], 2 sodium saline citrate [SSC]) at room temperature
and then washed twice for 15 minutes using buffer 2 (10%
SDS, 20 SSC) at room temperature. BAS 2500 Image Analy-
sis System and Multi Gauge V3.0 software (Fujifilm, Tokyo,
Japan) were used for quantitation. Ethidium bromide stain-
ing of rRNA was used for RNA loading control. 
6. Cell culture
Ten human GC cell lines, SNU-638, and AGS were 
obtained from the Korean cell line bank. RPMI 1640 (Wel-
gene, Daegu, Korea) supplemented with 10% fetal bovine
serum (Thermo Scientific, Waltham, MA) and 1% penicillin
and streptomycin (Life Technologies, Carlsbad, CA) was
used for cell culture. The cells were maintained at 37°C under
an atmosphere of 5% CO2-95% air. 
Transfection to AGS cells was performed one day after
seeding using Lipofectamine 2000 (Invitrogen).
Male Female
Variable WT mouse TG mouse WT mouse TG mouse
(n=6) (n=6) (n=3) (n=3)
Body weight 32.950 39.600 28.280 29.100
Spleen 0.057 0.056 0.059 0.061
Liver 0.089 0.089 0.059 0.061
Kidney, left 0.130 0.133 0.098 0.108
Kidney, right 0.139 0.133 0.105 0.111
Thymus 0.036 0.034 0.002 0.002
Heart 0.283 0.116 0.104 0.104
Lung 0.134 0.126 0.132 0.089
Brain 0.423 0.415 0.427 0.427
WBC (103/mm3) 2.36 1.30 . - . -
RBC (106/mm3) 7.36 7.82 . - . -
HGB (g/dL) 11.20 11.50 . - . -
HCT (L%) 30.00 32.60 . - . -
PLT (103/mm3) 678 665 . - . -
MCV 40.80 41.70 . - . -
MCH (pg) 15.30 14.80 . - . -
MCHC (g/dL) 37.40 35.50 . - . -
Neutrophil (%) 6.75 5.70 . - . -
Eosinophil (%) 0.10 0.00 . - . -
Basophil (%) 0.20 0.20 . - . -
Lymphocyte (%) 88.20 90.30 . - . -
Monocyte (%) 3.90 2.90 . - . -
WT, wild-type mouse; TG, miR-222/221 transgenic mouse; WBC, white blood cell; RBC, red blood cell; HGB, hemoglobin;
HCT, hematocrit; PLT, platelet count; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean
corpuscular hemoglobin concentration.
Table 1. Organ weight and blood chemistry test of miR-222/221 transgenic mice (56-week-old)
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7. Quantitative real-time polymerase chain reaction
One microgram of total RNA was used for single-stranded
cDNA using the SuperScript First Strand cDNA synthesis
(Life Technologies). RNA quantification was conducted by
real-time polymerase chain reaction (PCR) using the compar-
ative Ct method with the Bio-Rad iCycler Real-Time PCR
system. Real-time PCR was performed in a 20 µL final vol-
ume containing 10 µL of SYBR 2 master mix (Thermo Fisher
Scientific), 10 pmol of each primer in a volume of 1 µL, and
1 µL of cDNA. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) primer sets were used for normalization. Each
sample was run in triplicate (Bio-Rad Laboratories). Primers
for the amplification of mature miR-221 and miR-222 are pre-
sented in Supplementary Table 1.
8. Statistical analysis
Statistical analyses were performed using SPSS ver. 13.0
(SPSS Inc., Chicago, IL) and graphs were generated using
GraphPad Prism 5.0 (GraphPad Software Inc., San Diego,
CA). Chi-square was used to measure the carcinogenesis 
association between the miR-222/221 transgenic and wild-
type mice. p-values less than 0.05 are considered statistically
significant.
Results
1. Phenotype of transgenic mice and selection 
The expression level of pre-miRNA-222/221 and mature
miR-222/221 was increased in the stable cell line transfected
with miR-222/221 as compared to the cell line transfected
with pcDNA3 null vector (Fig. 2A). To examine whether off-
springs contained the injected foreign DNA, germ-line trans-
mission was tested by PCR using the CMV promoter primer
and miR-222 primer at 3 weeks of age, all mice were screened
by PCR (Fig. 2B). At 10 weeks of age, the expression levels
of pre-miRNA-222/221 and mature miR-222/221 were com-
pared between wild-type and transgenic mice in nine organs
(brain, thymus, heart, lung, stomach, liver, intestine, spleen,
and kidney) by northern blotting (Fig. 2C). miR-222/221 was
expressed in transgenic mice, but not in wild-type mice.
Compared to wild-type mice, transgenic mice strongly over-
expressed both pre-miRNA-222/221 and mature miR-222/
221 in the stomach, brain, lung, and kidney. The organ
weight and blood chemistry were investigated in 56-week-
old mice to compare the phenotype of transgenic and wild-
type mice. There was no difference in organ weight between
the two groups. When we compared body weights between
male mice, transgenic mice were about 20% heavier than
wild-type mice. The white blood cell (WBC) count was 1.8-
fold lower in transgenic mice in blood chemistry tests (Table 1).
2. Histological findings
MNU treated mice were euthanized at 36 weeks of age.
Transgenic and wild-type mice were randomly selected and
the expression levels of miR-222 and miR-221 were con-
firmed by northern blot and real-time PCR (Supplementary
Fig. S1). Approximately 85% of transgenic mice survived
until 36 weeks of age (Table 2). At the end of the experiment,
all surviving mice were euthanized, and their stomachs and
other organs were carefully examined. From the pathological
findings, after treatment with the carcinogen MNU, carci-
noma and other lesions, including hyperplasia, microcarci-
noma in adenoma, angiosarcoma, microscopic dysplasia,
adenoma in pylorus region, and squamous papilloma in the
fundus region, were detected in the mice stomachs. How-
ever, only flat serrated adenoma was observed from the 
intestines of three mice. From these results, adenoma and 
hyperplasia, the two most frequently observed pre-cancerous
lesions, were selected and included for MNU-induced multi-
gastric carcinogenesis steps. Representative histological 
images of normal, pre-cancerous lesions and carcinoma are
shown in Fig. 3. Hyperplasia was observed in 3.77% of the
wild-type mice and in 18.46% of the transgenic mice (p=0.020).
Adenoma was observed in 20.75% of the wild-type mice and
26.15% of the transgenic mice (p=0.522). Carcinoma was 
observed in 32.08% of the wild-type mice and 41.54% of the
transgenic mice (p=0.341). The frequency of hyperplasia, ade-
noma, and carcinoma was higher in transgenic mice, but the
difference was statistically significant only in hyperplasia
(Table 3). When hyperplasia and adenoma were combined
as a pre-cancerous lesion, it was observed in 44.62% of trans-
genic mice and 24.53% of wild-type mice; this difference was
statistically significant (p=0.033).
3. Cancer-related marker expression 
To test the correlation between cancer and miR-222/221 in
our in vivo model, cancer related markers were selected for
immunohistochemistry. CD31 was used as a marker of 
angiogenesis, Ki-67 was used to assess cell proliferation, and
cleaved caspase 3 was used as an apoptosis marker. More-
over, two antibodies against proteins encoded by two miR-
222/221 target genes, p27 and p57, were used to compare p27
and p57 protein expression in the stomachs of transgenic and
wild-type mice by immunohistochemistry. Based on our 
hypothesis, in transgenic mice overexpressing miR-222/221,
the expression of p27 and p57 should be repressed as com-
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Table 2. Mortality within 30 weeks and MNU intake of mice according to group
Group Total No. of mice No. of mice finally evaluated Dead No. of mice (%)
WT mouse 59 53 6 (10.16)
TG mouse 76 65 11 (14.47)
MNU, N-nitroso–N–methylurea; WT, wild-type mouse; TG, miR-222/221 transgenic mouse. 
Table 3. Percent of carcinoma and pre-cancerous lesions occurrence by histologic findings
Histological type WT Percentage TG Percentage p-value
Normal 23 43.40 9 13.85 < 0.001*
Hyperplasia 2 3.77 12 18.46 0.020*
Adenoma 11 20.75 17 26.15 0.522
Carcinoma 17 32.08 27 41.54 0.341
Total 53 65 0.001*
WT, wild-type mouse; TG, miR-222/221 transgenic mouse. *Statistically significant. 
Normal Hyperplasia
Adenoma Carcinoma
Fig. 3. Representative histological images of normal, pre-cancerous lesions, and carcinoma in transgenic and wild-type mice
(A, C, D, H&E staining, 40; B, H&E staining, 100). 
A B
DC
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Fig. 4. Cancer-related markers analyzed by immunohistochemistry. (A) Histological analysis of the stomachs of MNU-
treated mice. CD31 and Ki-67 expression increased in transgenic (TG) mice compared to that in wild-type (WT) mice (100).
No significant difference was observed in caspase 3, p57, and p27 expression. (B) Histological analysis of the stomachs of
MNU-untreated mice. p27 expression was similar in the stomachs of WT and TG mice.
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pared to that in wild-type mice. However, there was no sig-
nificant difference in term of p27 and p57 expression between
the transgenic and wild-type mice. Compared to wild-type
mice, in transgenic mice, CD31 (angiogenesis marker) and
Ki-67 (proliferation marker) were highly expressed, suggest-
ing that cancer-related biological processes, angiogenesis and
proliferation, were activated. However, the expression of
cleaved caspase 3 (apoptosis marker), p27, and p57 was not
significantly different between the two groups (Fig. 4A). 
Additionally, p27 expression was similar in the stomach of
untreated wild-type and transgenic mice (Fig. 4B). 
Discussion
Despite the significant number of patients with gastric can-
cer, surgery is often the only treatment option because of the
many side effects of chemotherapy and radiation therapy
[8,17]. Surgery is also limited to local treatment. For this rea-
son, miRNA has gained much attention due to its assumed
role in carcinogenesis. However, the molecular pathology of
gastric cancer remains poorly understood even though gas-
tric cancer is a major health burden throughout the world.
Therefore, the study of miRNAs implicated in gastric cancer
formation is urgent and may provide opportunities to 
develop new means for diagnosis and treatment of gastric
cancer. In addition, the accurate function of miRNAs in vivo
still need to be further investigated. Many groups attempted
to generate miRNA knockout or transgenic mice to validate
the specificity and efficiency of microRNA in vivo animal
models.
Regarding the phenotype of the miR-222/221 transgenic
mice, the body weight of male transgenic mice was about
20% higher than that of the control group whereas no signif-
icant difference was observed in term of body weight 
between transgenic and wild-type female mice. The result of
blood testing indicated unique differences in WBC and
monocytes. Levels of WBC and monocytes were significantly
lower by 1.8-fold and 1.3-fold, respectively, in transgenic
mice than in wild-type mice. WBC and monocytes are related
to immune response and, therefore, aberrantly low levels of
WBC and monocytes result in a decreased ability to fight
virus or other pathogens. This shortage of immune response
may contribute to the enhanced gastric cancer development
in miR-222/221 transgenic mice. After euthanasia, the Swiss
roll technique was performed on all mice to detect abnormal
intestinal lesions. No carcinoma or cancer-related lesions
were detected in the intestine, but flat serrated adenoma was
observed in three transgenic mice.
When the phenotype of transgenic mice was examined at
56 weeks of age, no aberrant lesions were observed macro-
scopically and during histological examination. This result
suggested that miR-222/221 overexpression in these trans-
genic mice was not sufficient to cause gastric carcinogenesis
by itself. Therefore, MNU, which is a well-known rodent car-
cinogenic, was administered to both transgenic and wild-
type mice to promote gastric carcinogenesis using a previo-
usly described protocol [14-16,18].
The MNU-induced mouse models for gastric carcinogen-
esis have been widely used to study carcinogenesis of the
stomach [14-16,18]. These animal models have been used not
only to investigate the pathogenesis of gastric carcinogenesis,
but also to identify tumor promoters and chemopreventive
agents [16,19]. To determine the accurate time at which car-
cinogenesis and cancer-related lesions could be detected, five
MNU-treated mice from each group were euthanized at 27
weeks of age, but no significant histological difference 
between transgenic and wild-type mice was observed. This
can be explained by the fact that mice are known to be rela-
tively resistant to MNU. Therefore, a longer period is 
required to induce gastric carcinoma in C57BL/6J mice
[15,19-21]. When the MNU-treated mice were euthanized at
36 weeks of age, MNU-induced gastric carcinogenesis steps
were detected.
After euthanasia at 36 weeks of age, pathological exami-
nation was performed to evaluate whether the lesions 
observed were related to cancer. The alkylating agent MNU
induces the development of different patterns of cancer-
related lesions. For instance, hyperplasia is frequently 
observed when using MNU, as previously reported by many
groups [14,15,19]. The reason why hyperplasia is often 
detected in MNU-induced gastric carcinogenesis models is
not fully understood, but it is commonly found in other car-
cinogen-induced gastric carcinogenesis models. The result
was also similar to macroscopic findings. The whole stomach
of the mice was thickened and stiff with pre-cancerous 
lesions. 
Recent studies revealed that miR-222/221 is overexpressed
in several types of cancer and has oncogenic effects [22-24].
In most cases, in vitro studies have been reported, but one
group recently developed an in vivo model of liver cancer.
The transgenic model, in which miR-221 is expressed specif-
ically in the liver, was developed and characterized by the
appearance of spontaneous liver tumors in a fraction of male
mice and a strong acceleration of tumor development in
100% of mice treated with diethylnitrosamine [25]. However,
in our study, carcinoma occurrence was not statistically sig-
nificant, while frequently observed pre-cancerous lesions
were statistically significant. In our transgenic model, the 
occurrence of carcinoma could not be dramatically induced.
This can be explained by the fact that we did not use a pro-
moter specific for the stomach and could not transcription-
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ally control the expression of miR-222/221 when the trans-
genic mouse model was developed. In the case of the miR-
221 liver cancer transgenic mouse, a liver-specific promoter
was used and the overexpression of miR-221 was induced.
Our transgenic mice expressed miR-222/221 in all organs.
Thus, showing a strong effect of miR-222/221 in the stomach
was expected to be difficult. 
Ultimately, even though assessing the expression of p27
was difficult because of the changes (mRNA, protein, and
immunohistochemistry) induced by MNU, we demonstrated
that the gastric carcinogenic effect of miR-222/221 with the
help of MNU was more frequently detected in transgenic
mice than in wild-type mice, although it was a mild effect. 
Conclusion
This study showed that MNU-induced pre-cancerous 
lesions were enhanced in miR-222/221 overexpressing trans-
genic mice compared to that in wild-type mice but miR-
222/221 does not affect tumorigenesis itself.
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